Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.22

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.22.

Several analysts have issued reports on FOLD shares. The Goldman Sachs Group lowered their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in Amicus Therapeutics during the 4th quarter worth about $132,000. AlphaQuest LLC boosted its position in Amicus Therapeutics by 635.1% during the fourth quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company's stock worth $101,000 after purchasing an additional 9,272 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in Amicus Therapeutics by 35.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock worth $2,850,000 after purchasing an additional 79,602 shares during the period. Swiss National Bank boosted its position in Amicus Therapeutics by 0.7% during the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after purchasing an additional 3,200 shares during the period. Finally, Cibc World Markets Corp acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $259,000.

Amicus Therapeutics Trading Down 0.9%

NASDAQ FOLD traded down $0.06 during mid-day trading on Wednesday, hitting $6.37. The company's stock had a trading volume of 561,970 shares, compared to its average volume of 3,788,130. Amicus Therapeutics has a 52-week low of $5.51 and a 52-week high of $12.65. The stock's fifty day simple moving average is $6.09 and its two-hundred day simple moving average is $7.84. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47. The firm has a market capitalization of $1.96 billion, a P/E ratio of -70.71 and a beta of 0.51.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.